Nexus Facility Further Purifies CBD into Premium Product
VANCOUVER, BC / ACCESSWIRE / October 8, 2019 / Stillcanna Inc. (OTC PINK:SCNNF) (CSE:STIL) (FSE:A2PEWA) ('STIL' or the 'Company') would like to announce its Polish extraction facility Nexus has successfully refined its Distillate oils to the highest possible purity.
There are no definitions for the words CBD oil, CBD Distillate, or Raw Oil no standards exist. But, there is one definable goal in the manufacturing of CBD oil, a clear honey colored oil with a content of over 90% CBD by volume. This level of refinement is a culmination of knowledge, experience and equipment, which eludes many in the industry; it is one of the most expensive and sought after products on the market today.
'Stillcanna has always intended to define and refine the future of CBD,' pointed out Jason Dussault CEO of Stillcanna. 'We continue to implement our mandate of volume manufacturing while deploying the highest standards of processing and products. Being able to produce such a high quality product puts Stillcanna in a small and elite group of global manufacturers in the seed to CBD supply chain.'
The Purest of CBD Distillate 'Honey Oil' Manufactured in Stillcanna's Nexus Facility in Poland.
The production of honey oil is another step for Stillcanna towards commercial scale manufacturing this quarter. Additionally, in order to create CBD isolate, one should start with highly concentrated CBD Distillate. The cleaner the Distillate, the more efficient is the process of binding the CBD molecules to create a pure CBD crystal 'Isolate'. The Company remains on track to ship CBD products in Q4 to existing and new customers.
About Stillcanna Inc.
Stillcanna Inc. (CSE:STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on the large scale manufacturing of CBD in Europe. The Company believes its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, a multi-generational hemp agricultural firm that is expected to increase the Company's market share in the European CBD industry.
On Behalf of the Board
Jason Dussault, CEO
Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including that the Company should be in full commercial scale production this quarter.
Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as 'intends' or 'anticipates', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'should' or 'would' occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the Company's Nexus facility has successfully refined its Distillate oils to the highest possible purity.
Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that CBD Honey Oil it is one of the most expensive and sought after product on the market today and that The Company remains on track to ship CBD products in Q4 to existing and new customers.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.
SOURCE: StillCanna Inc.
View source version on accesswire.com: